Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifampin

FDA-approved product (capsule, oral), marketed as Rifadin, Rifampin, Rimactane.

Registered studies
50+
Lab records
242
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifampin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB02; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifampin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 16 of 19 lab records
  • M. tuberculosis: measured active in 207 of 216 lab records
Open Rifampin in ChEMBL Registered studies below
Show the latest 150 of 242 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifampin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)

    NCT04721795 · start 2021-01-19

    Registered record
    Registry ID
    NCT04721795
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis
    Interventions
    Atorvastatin with standard anti tuberculosis drugs; Standard anti tuberculosis drugs only
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-01-19
    Completion
    2022-06-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis
    InterventionAtorvastatin with standard anti tuberculosis drugs; Standard anti tuberculosis drugs only
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

    NCT04537715 · start 2020-04-23

    Registered record
    Registry ID
    NCT04537715
    Conditions
    All Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Diffuse Large B-Cell Lymphoma (DLBCL); Epithelioid Sarcoma (ES); Synovial Sarcoma; Renal Medullary Carcinoma; Mesothelioma; Rhabdoid Tumor
    Interventions
    Tazemetostat; Itraconazole; Tazemetostat; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-04-23
    Completion
    2023-04-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAll Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor +8 more
    InterventionTazemetostat; Itraconazole; Tazemetostat; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

    NCT03915366 · start 2020-03-01

    Registered record
    Registry ID
    NCT03915366
    Conditions
    Pneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    Interventions
    Valganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-03-01
    Completion
    2025-01-31
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    InterventionValganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

    NCT05134337 · start 2020-02-12

    Registered record
    Registry ID
    NCT05134337
    Conditions
    Healthy Volunteers
    Interventions
    LOXO-305; Itraconazole; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-12
    Completion
    2020-10-30
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLOXO-305; Itraconazole; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

    NCT03486314 · start 2018-08-13

    Registered record
    Registry ID
    NCT03486314
    Conditions
    Advanced Solid Neoplasm
    Interventions
    Pevonedistat; Rifampin; Docetaxel; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-08-13
    Completion
    2021-02-28
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Neoplasm
    InterventionPevonedistat; Rifampin; Docetaxel; Carboplatin +1 more
    PhasePhase 1
    Registry statusCompleted

  • DDI Study Between Dorzagliatin and Rifampicin

    NCT04080609 · start 2018-03-27

    Registered record
    Registry ID
    NCT04080609
    Conditions
    Drug Interaction
    Interventions
    Dorzagliatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-27
    Completion
    2018-04-17
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction
    InterventionDorzagliatin
    PhasePhase 1
    Registry statusCompleted

  • S. Aureus Decolonization in HPN Patients.

    NCT03173053 · start 2018-02-08

    Registered record
    Registry ID
    NCT03173053
    Conditions
    Staphylococcus Aureus; Motility Disorder
    Interventions
    Doxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin; Clarithromycin; Ciprofloxacin; Fusidic Acid; Rifampin; Chlorhexidine; Mupirocin; Betadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2021-10-14
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; Motility Disorder
    InterventionDoxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin +7 more
    PhaseNot applicable
    Registry statusTerminated

  • Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

    NCT03174184 · start 2017-08-23

    Registered record
    Registry ID
    NCT03174184
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD; Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet; Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-23
    Completion
    2022-05-13
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD +2 more
    PhasePhase 2
    Registry statusCompleted

  • The Impact of Pharmacists' Interventions on the Quality of Life of HIV-TB Co-infection Outpatients in Indonesia

    NCT04325438 · start 2017-04-01

    Registered record
    Registry ID
    NCT04325438
    Conditions
    Pharmaceutical Care; HIV/AIDS; Tuberculosis
    Interventions
    Pharmaceutical Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2019-03-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmaceutical Care; HIV/AIDS; Tuberculosis
    InterventionPharmaceutical Care
    PhaseNot applicable
    Registry statusCompleted

  • Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

    NCT03048110 · start 2017-02-15

    Registered record
    Registry ID
    NCT03048110
    Conditions
    Biological Availability
    Interventions
    BAY1841788 (ODM-201); Itraconazole; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-02-15
    Completion
    2017-07-19
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiological Availability
    InterventionBAY1841788 (ODM-201); Itraconazole; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Phase 2a Study of PBTZ169

    NCT03334734 · start 2016-12-16

    Registered record
    Registry ID
    NCT03334734
    Conditions
    Tuberculosis
    Interventions
    PBTZ169; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-12-16
    Completion
    2018-02-22
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPBTZ169; Isoniazid
    PhasePhase 2
    Registry statusTerminated

  • Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

    NCT02832778 · start 2016-11-21

    Registered record
    Registry ID
    NCT02832778
    Conditions
    HIV
    Interventions
    Efavirenz; tenofovir /emtricitabine; tenofovir/lamivudine; lamivudine/zidovudine; Rifinah or local generics
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-11-21
    Completion
    2018-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEfavirenz; tenofovir /emtricitabine; tenofovir/lamivudine; lamivudine/zidovudine +1 more
    PhasePhase 1
    Registry statusUnknown

  • A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

    NCT02875223 · start 2016-08-31

    Registered record
    Registry ID
    NCT02875223
    Conditions
    Lymphoma, Non-Hodgkin; Neoplasms
    Interventions
    CC-90011; Rifampicin; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-08-31
    Completion
    2024-03-25
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Non-Hodgkin; Neoplasms
    InterventionCC-90011; Rifampicin; Itraconazole
    PhasePhase 1
    Registry statusTerminated

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

    NCT02387242 · start 2015-02

    Registered record
    Registry ID
    NCT02387242
    Conditions
    Tuberculosis
    Interventions
    Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2015-02
    Completion
    2017-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampicin
    PhasePhase 1
    Registry statusSuspended